Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
M. Joseph John(The University of Texas Health Science Center at Houston), Aby Abraham(Christian Medical College, Vellore), Tulika Seth(Manipal Academy of Higher Education), Prantar Chakrabarti(Medical College and Hospital, Kolkata), Cecil Ross(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Neeraj Siddharthan(Amrita Institute of Medical Sciences and Research Centre), Maitreyee Bhattacharyya, Rohan Kolla(Novo Nordisk (India)), Trine Hansen(Novo Nordisk (Denmark)), Shashikant Apte, Chandrakala Shanmukhaiah
Cited by 2
Related Papers
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
|New England Journal of Medicine|2016|494
Platelet activation determines the severity of thrombocytopenia in dengue infection
|Scientific Reports|2017|198
Autologous stem cell transplantation in refractory Asherman′s syndrome: A novel cell based therapy
|Journal of Human Reproductive Sciences|2014|184
Environmental and occupational determinants of lung cancer
|Translational Lung Cancer Research|2019|171
Recommendations for screening and early detection of common cancers in India
|The Lancet Oncology|2015|125